INTERACTION OF THE NEU P185 AND EGF RECEPTOR TYROSINE KINASES - IMPLICATIONS FOR CELLULAR-TRANSFORMATION AND TUMOR-THERAPY

被引:76
作者
DOUGALL, WC
QIAN, XL
GREENE, MI
机构
[1] Center for Receptor Biology, Division of Immunology, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
关键词
NEU P185 PROTEIN; C-ERBB-2; EPIDERMAL GROWTH FACTOR RECEPTOR; TRANSFORMATION;
D O I
10.1002/jcb.240530108
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Growth factor receptors such as the epidermal growth factor receptor (EGFR) and the p185c-neu protein serve vital roles in the transduction of differentiation, developmental, or mitogenic signaling within normal cells. Two methods of analysis suggest that the inappropriately high expression of either protein tyrosine kinase promotes malignant transformation. First, data from in vitro experiments indicate that overexpression of either EGFR or p185c-neu (or the human homolog c-erbB-2) transforms cell-lines. Second, analysis of primary tumors and tumor cell-lines derived from many epithelial tissues (breast, stomach, ovary, and pancreas) show growth factor receptor gene amplification and elevated protein levels. The physical and functional interaction of p185c-neu and EGFR leads to the formation of a highly active, heterodimeric tyrosine kinase complex which synergistically activates cellular transformation. Anti-receptor antibodies have shown potential utility for the down modulation of these cell-surface proteins and suppression of the malignant phenotype. Design of organic antibody ''mimetics'' based on the structure of antireceptor antibodies may provide useful therapies and biological reagents to affect growth factor receptor function. (C) 1993 Wiley-Liss, Inc.
引用
收藏
页码:61 / 73
页数:13
相关论文
共 52 条
[31]   PHOSPHORYLATION PROCESS INDUCED BY EPIDERMAL GROWTH-FACTOR ALTERS THE ONCOGENIC AND CELLULAR NEU (NGL) GENE-PRODUCTS [J].
KOKAI, Y ;
DOBASHI, K ;
WEINER, DB ;
MYERS, JN ;
NOWELL, PC ;
GREENE, MI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (15) :5389-5393
[32]   ENHANCED EXPRESSION OF EPIDERMAL GROWTH-FACTOR RECEPTOR CORRELATES WITH ALTERATIONS OF CHROMOSOME-7 IN HUMAN PANCREATIC-CANCER [J].
KORC, M ;
MELTZER, P ;
TRENT, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (14) :5141-5144
[33]  
MAGUIRE HC, 1990, PATHOBIOLOGY, V58, P297
[34]   CARBOXYL-TERMINAL DELETION AND POINT MUTATIONS DECREASE THE TRANSFORMING POTENTIAL OF THE ACTIVATED RAT NEU ONCOGENE PRODUCT [J].
MIKAMI, Y ;
DAVIS, JG ;
DOBASHI, K ;
DOUGALL, WC ;
MYERS, JN ;
BROWN, VI ;
GREENE, MI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (16) :7335-7339
[35]  
PRESS MF, 1990, ONCOGENE, V5, P953
[36]  
PRIGENT SA, 1992, ONCOGENE, V7, P1273
[37]   P185C-NEU AND EPIDERMAL GROWTH-FACTOR RECEPTOR ASSOCIATE INTO A STRUCTURE COMPOSED OF ACTIVATED KINASES [J].
QIAN, XL ;
DECKER, SJ ;
GREENE, MI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (04) :1330-1334
[38]   DESIGN AND SYNTHESIS OF A MIMETIC FROM AN ANTIBODY COMPLEMENTARITY-DETERMINING REGION [J].
SARAGOVI, HU ;
FITZPATRICK, D ;
RAKTABUTR, A ;
NAKANISHI, H ;
KAHN, M ;
GREENE, MI .
SCIENCE, 1991, 253 (5021) :792-795
[39]  
SEGATTO O, 1990, New Biologist, V2, P187
[40]   MONOCLONAL-ANTIBODY THERAPY OF HUMAN CANCER - TAKING THE HER2 PROTOONCOGENE TO THE CLINIC [J].
SHEPARD, HM ;
LEWIS, GD ;
SARUP, JC ;
FENDLY, BM ;
MANEVAL, D ;
MORDENTI, J ;
FIGARI, I ;
KOTTS, CE ;
PALLADINO, MA ;
ULLRICH, A ;
SLAMON, D .
JOURNAL OF CLINICAL IMMUNOLOGY, 1991, 11 (03) :117-127